Clinical Trial NU FC11S02
- Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma (OER-SAR-043)
- Principal Investigator
- Mark Agulnik
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.NU FC11S02
- The goal of this study is to find out what effects, good and/or bad, pazopanib has on patients and their angiosarcoma.
- The standard treatment for angiosarcoma is surgery to remove the cancer; however, these tumors have a high chance of returning, leading to the need for systemic therapy. Few effective systemic therapy options exist for angiosarcoma. Pazopanib is a drug that has shown encouraging activity in previous studies of other types of sarcomas. In laboratory testing pazopanib has shown anti-angiogenic effects (it stops or slows the growth of blood vessels to the cancer). Other drugs that have anti-angiogenic effects have been effective in fighting angiosarcoma, so researchers hope that pazopanib will have therapeutic activity in this disease.
Some of the eligibility criteria include:
- Participants must have angiosarcoma that cannot be removed with surgery.
- Participants must have had at least one prior treatment regimen for their angiosarcoma.
- Participants must be 18 or older.
- Description of Treatment
- Participants in this study will take pazopanib pills by mouth every day until the pills stop working or until the participant has too many side effects.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Mark Agulnik
- TPF Induction chemotherapy and ABT-888 (Veliparib) – a Phase 1/Randomized Phase 2 Study in Patients w/ Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
- A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma
- A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
- Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
- A Phase 1 Study to Evaluate the Safety, Tolerability, and Efficacy of MEDI4736 in Combination with Tremelimumab or Tremelimumab Alone in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients with Soft Tissue Sarcoma
- An Open-Label Study to Evaluate the Pharmacokinetics of Doxorubicin following the Concomitant Intravenous Administration of Olaratumab (IMC-3G3) to Patients with Advanced Soft Tissue Sarcoma
- A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator’s Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy
- Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
- A Phase II Study of Pazopanib with Oral Topotecan in Patients with Metastatic and Non-resectable Soft Tissue and Bone Sarcomas
- A Blanket Protocol to Study Oral Regorafenib in Patients with Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing–Like Sarcomas
last updated: 05-Sep-15 12:42 AM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.